omniture
logo
Search
南京维立志博生物科技股份有限公司 NANJING LEADS BIOLABS CO. LTD
Media Room

Photo News

rss
A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

2024-04-30 20:16 1590